Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) have been given an average recommendation of “Buy” by the six analysts that are presently covering the stock, Marketbeat reports. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $23.80.

Several research analysts recently commented on the company. Leerink Partners reduced their target price on Lexeo Therapeutics from $20.00 to $19.00 and set an “outperform” rating for the company in a research report on Wednesday, November 13th. Chardan Capital boosted their target price on Lexeo Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Finally, HC Wainwright upped their price target on shares of Lexeo Therapeutics from $21.00 to $23.00 and gave the stock a “buy” rating in a research report on Thursday, November 14th.

Institutional Investors Weigh In On Lexeo Therapeutics

A number of institutional investors have recently made changes to their positions in LXEO. BNP Paribas Financial Markets boosted its position in shares of Lexeo Therapeutics by 184.2% during the third quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company’s stock worth $50,000 after purchasing an additional 3,591 shares in the last quarter. Values First Advisors Inc. acquired a new position in Lexeo Therapeutics during the third quarter valued at approximately $67,000. JPMorgan Chase & Co. boosted its holdings in shares of Lexeo Therapeutics by 135.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 10,278 shares of the company’s stock valued at $93,000 after buying an additional 5,915 shares during the last quarter. Rhumbline Advisers grew its position in shares of Lexeo Therapeutics by 37.3% in the 2nd quarter. Rhumbline Advisers now owns 13,357 shares of the company’s stock valued at $214,000 after acquiring an additional 3,627 shares during the period. Finally, MetLife Investment Management LLC grew its holdings in Lexeo Therapeutics by 121.5% during the third quarter. MetLife Investment Management LLC now owns 14,223 shares of the company’s stock worth $129,000 after purchasing an additional 7,803 shares during the period. 60.67% of the stock is owned by institutional investors and hedge funds.

Lexeo Therapeutics Stock Down 5.5 %

Shares of LXEO opened at $5.19 on Friday. The company has a 50-day simple moving average of $6.93 and a 200-day simple moving average of $9.62. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.95 and a current ratio of 5.95. Lexeo Therapeutics has a 52 week low of $4.78 and a 52 week high of $22.33. The firm has a market capitalization of $171.63 million, a P/E ratio of -1.64 and a beta of 3.08.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.